ClinicalTrials.gg
TerminatedNCT03985878Updated Aug 18, 2023Results posted

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

A Phase 2 interventional study of Eteplirsen in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Terminated at 4 sites in 4 countries. Open to male participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
2 Years to 5 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
6th of 11
15 · median 15
Started
2019
the only one that year
Phase 2
7 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 9th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 5 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male participants with DMD who have successfully completed the 96-week eteplirsen Study 4658-102.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • DMD
  • Duchenne
  • Eteplirsen
  • Dystrophy
  • Dystrophin
  • Exon Skipping
  • Exon 51
  • Ambulatory
  • Pediatric
04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant successfully completes 96 weeks of treatment in Study 4658-102.

Exclusion criteria

Exclusion Criteria:

  • Participant has a prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the participant, or make it unlikely that the course of treatment or follow-up would be completed, or impair the assessment of study results.

Other inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Eteplirsen

    Participants will receive eteplirsen via IV infusions, once weekly, for up to 284 weeks.

    Drug: Eteplirsen

Interventions

  • Eteplirsen IV infusion once weekly.

    Also known as: AVI-4658, EXONDYS 51, EXONDYS

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.

    Time frame: Up to 162 weeks

  2. Number of Participants Experiencing Death Due to Adverse Events

    A summary of all deaths regardless of causality is located in the 'Reported Adverse Events' section.

    Time frame: Up to 162 weeks

  3. Number of Participants Experiencing Adverse Events of Special Interest (AESIs)

    AESIs were defined as any AE that was of scientific and medical concern specific to study treatment, for which ongoing and rapid communication by the Investigator to the sponsor was appropriate. AESIs included findings potentially indicative of hepatic and renal abnormalities, hypersensitivity, and thrombocytopenia. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.

    Time frame: Up to 162 weeks

07

Results

Posted Aug 18, 2023
Limitations and caveats
In an effort to reduce clinical trial burden on participants while ensuring continued treatment if desired, pending commercial availability of eteplirsen, participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment.

Participant flow

In an effort to reduce clinical trial burden on participants while ensuring continued treatment if desired, pending commercial availability of eteplirsen, participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment.

Participant flow — Overall Study
MilestoneEteplirsen
Started15
Received at least 1 dose of study drug15
Completed0
Not completed15
Withdrew: Transitioned to another sarepta study2
Withdrew: Study terminated by sponsor12
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants Experiencing Adverse Events (AEs)

A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.

Time frame:
Up to 162 weeks
Reported as:
Number · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsEteplirsen
Number of Participants Experiencing Adverse Events (AEs)15
PrimaryNumber of Participants Experiencing Death Due to Adverse Events

A summary of all deaths regardless of causality is located in the 'Reported Adverse Events' section.

Time frame:
Up to 162 weeks
Reported as:
Number · Participants
Number of Participants Experiencing Death Due to Adverse Events
ParticipantsEteplirsen
Number of Participants Experiencing Death Due to Adverse Events0
PrimaryNumber of Participants Experiencing Adverse Events of Special Interest (AESIs)

AESIs were defined as any AE that was of scientific and medical concern specific to study treatment, for which ongoing and rapid communication by the Investigator to the sponsor was appropriate. AESIs included findings potentially indicative of hepatic and renal abnormalities, hypersensitivity, and thrombocytopenia. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.

Time frame:
Up to 162 weeks
Reported as:
Number · Participants
Number of Participants Experiencing Adverse Events of Special Interest (AESIs)
ParticipantsEteplirsen
Number of Participants Experiencing Adverse Events of Special Interest (AESIs)0

Adverse events

Collected over Up to 162 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eteplirsen0/15 (0%)1/15 (6.7%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventEteplirsen
InfluenzaInfections and infestations1/15
Most frequent other events
Showing 10 of 101
Most frequent other events
EventEteplirsen
CoughRespiratory, thoracic and mediastinal disorders12/15
RhinorrhoeaRespiratory, thoracic and mediastinal disorders9/15
PyrexiaGeneral disorders9/15
NasopharyngitisInfections and infestations8/15
Corona virus infectionInfections and infestations7/15
RhinitisInfections and infestations6/15
HeadacheNervous system disorders6/15
ConstipationGastrointestinal disorders5/15
VomitingGastrointestinal disorders5/15
ContusionInjury, poisoning and procedural complications5/15

Baseline characteristics

Safety Set: all participants who received eteplirsen.

Age, Continuous
Age, Continuous(years)Eteplirsen
Mean3.7 ± 1.10
Sex: Female, Male
Sex: Female, Male(Participants)Eteplirsen
Female0
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eteplirsen
Hispanic or Latino0
Not Hispanic or Latino7
Unknown or Not Reported8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eteplirsen
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported6
08

Study locations

4 sites
  • UZ-Gent
    Gent, 9000, Belgium
  • Hopital Trousseau, Bâtiment lemariey
    Paris, 75021, France
  • Fondazione Policlinico Universitario Agostino Gemelli, UOC Neuropsichiatria Infantile
    Rome, 00168, Italy
  • UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre
    London, England WC1N 1EH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Aug 2022, 38 months.

Results were first posted in Aug 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2019
First posted
Jun 14, 2019
StartActual
Jun 26, 2019
Primary completionActual
Aug 31, 2022
CompletionActual
Aug 31, 2022
Results first posted
Aug 18, 2023
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03985878
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
Jun 26, 2019
Primary completion
Aug 31, 2022
Completion
Aug 31, 2022
Results posted
Aug 18, 2023
Last update
Aug 18, 2023

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion